These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 17479541)

  • 1. Preclinical pharmacokinetics and interspecies scaling of ragaglitazar, a novel biliary excreted PPAR dual activator.
    Pavankuamr VV; Vinu CA; Mullangi R; Srinivas NR
    Eur J Drug Metab Pharmacokinet; 2007; 32(1):29-37. PubMed ID: 17479541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allometric prediction of the human pharmacokinetic parameters for naveglitazar.
    Ahlawat P; Srinivas NR
    Eur J Drug Metab Pharmacokinet; 2008; 33(3):187-90. PubMed ID: 19007045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats.
    Jagannath K; Chaluvadi MR; Mullangi R; Mamidi NV; Srinivas NR
    Biopharm Drug Dispos; 2004 Oct; 25(7):323-8. PubMed ID: 15386480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys.
    Hosagrahara VP; Chandrasena G; Chang SY; Koplowitz B; Hariharan N; Cheng PT; Humphreys WG
    Xenobiotica; 2006 Dec; 36(12):1227-38. PubMed ID: 17162469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interspecies scaling: prediction of human biliary clearance and comparison with QSPKR.
    Morris ME; Yang X; Gandhi YA; Bhansali SG; Benincosa LJ
    Biopharm Drug Dispos; 2012 Jan; 33(1):1-14. PubMed ID: 22170504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interspecies scaling of biliary excreted drugs.
    Mahmood I; Sahajwalla C
    J Pharm Sci; 2002 Aug; 91(8):1908-14. PubMed ID: 12115817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards a better prediction of peak concentration, volume of distribution and half-life after oral drug administration in man, using allometry.
    Sinha VK; Vaarties K; De Buck SS; Fenu LA; Nijsen M; Gilissen RA; Sanderson W; Van Uytsel K; Hoeben E; Van Peer A; Mackie CE; Smit JW
    Clin Pharmacokinet; 2011 May; 50(5):307-18. PubMed ID: 21456631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice, rats, and monkeys.
    Yi P; Hadden CE; Annes WF; Jackson DA; Peterson BC; Gillespie TA; Johnson JT
    Drug Metab Dispos; 2007 Jan; 35(1):51-61. PubMed ID: 17012539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo.
    Egerod FL; Nielsen HS; Iversen L; Thorup I; Storgaard T; Oleksiewicz MB
    Biomarkers; 2005; 10(4):295-309. PubMed ID: 16240504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interspecies scaling of biliary excreted drugs: a comparison of several methods.
    Mahmood I
    J Pharm Sci; 2005 Apr; 94(4):883-92. PubMed ID: 15736194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist.
    Ward KW; Azzarano LM; Bondinell WE; Cousins RD; Huffman WF; Jakas DR; Keenan RM; Ku TW; Lundberg D; Miller WH; Mumaw JA; Newlander KA; Pirhalla JL; Roethke TJ; Salyers KL; Souder PR; Stelman GJ; Smith BR
    Drug Metab Dispos; 1999 Nov; 27(11):1232-41. PubMed ID: 10534306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interspecies scaling of biliary excreted drugs: prediction of human clearance and volume of distribution.
    Mahmood I
    Drug Metabol Drug Interact; 2012; 27(3):157-64. PubMed ID: 23092793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes.
    Skrumsager BK; Nielsen KK; Müller M; Pabst G; Drake PG; Edsberg B
    J Clin Pharmacol; 2003 Nov; 43(11):1244-56. PubMed ID: 14551179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
    Deguchi T; Watanabe N; Kurihara A; Igeta K; Ikenaga H; Fusegawa K; Suzuki N; Murata S; Hirouchi M; Furuta Y; Iwasaki M; Okazaki O; Izumi T
    Drug Metab Dispos; 2011 May; 39(5):820-9. PubMed ID: 21282406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous prediction of human pharmacokinetic parameters for ketorolac, a non-steroidal anti-inflammatory agent, using allometry approach.
    Gilibili RR; Mullangi R; Srinivas NR
    Eur J Drug Metab Pharmacokinet; 2011 Jun; 36(2):87-93. PubMed ID: 21380569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of Human Pharmacokinetics of Ulixertinib, a Novel ERK1/2 Inhibitor from Mice, Rats, and Dogs Pharmacokinetics.
    Suresh PS; Jairam RK; Chandrasekhar DV; Vinod AB; Hiremath RA; Raj A; Zainuddin M; Bhamidipati RK; Mullangi R
    Eur J Drug Metab Pharmacokinet; 2018 Aug; 43(4):453-460. PubMed ID: 29470718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihypertensive effect of ragaglitazar: a novel PPARalpha and gamma dual activator.
    Mamnoor PK; Hegde P; Datla SR; Damarla RK; Rajagopalan R; Chakrabarti R
    Pharmacol Res; 2006 Aug; 54(2):129-35. PubMed ID: 16651004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interspecies pharmacokinetic scaling of oltipraz in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics.
    Bae SK; Lee SJ; Kim YG; Kim SH; Kim JW; Kim T; Lee MG
    Biopharm Drug Dispos; 2005 Apr; 26(3):99-115. PubMed ID: 15723427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of saroglitazar magnesium, a dual PPAR-α/γ agonist for treatment of dyslipidemia and metabolic disorders.
    Patel H; Giri P; Patel P; Singh S; Gupta L; Patel U; Modi N; Shah K; Jain MR; Srinivas NR; Patel P
    Xenobiotica; 2018 Dec; 48(12):1268-1277. PubMed ID: 29224415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
    Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X
    Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.